Table 5 Clinical characteristics and imaging findings according to the distribution of late gadolinium enhancement (LGE) and fat infiltration in DM2 and FSHD1 patients at baseline and at follow-up
| Â | All DM2 patients | DM2 LGE (+) | DM2 Fat (+) | |||
|---|---|---|---|---|---|---|
Type of Arrhythmias | Baseline (n = 32) | Follow-up n = 22 | Baseline (n = 5) | Follow-up n = 6 | Baseline n = 6 | Follow-up n = 7 |
SVT (n) | 2 | 9 | – | 5 | – | 5 |
Non-sustained VT n (n) | – | – | – | – | – | – |
Frequent PVC (≥1000/24h) (n) | – | – | – | – | – | – |
AV Block I (n) | 4 | 5 | 2 | 2 | 2 | 2 |
AV Block II (n) | – | 1 | – | – | – | – |
LBBB | 1 | 1 | 1 | 1 | 1 | 1 |
RBBB | 1 | 2 | – | 1 | – | – |
LAH | 2 | 3 | – | 1 | – | – |
LGE location and global volume | Â | Â | 5 | 6 | Â | Â |
Inferolateral basal (n)) | 5 | 6 | 5 | 6 | 1 | 3 |
Anterolateral basal (n) | – | 2 | – | 2 | – | – |
Septal (n) | 1 | 1 | 1 | 1 | – | – |
LGE area - mean (%) | Â | Â | 8.4 | 17.6 | Â | Â |
Fat apical | Â | Â | Â | Â | 6 | 7 |
Medical therapy | Â | Â | Â | Â | Â | Â |
Beta blockers (n) | 1 | 3 | – | 1 | – | 1 |
ACE, Sartans (n) | 4 | 10 | 1 | 2 | – | 2 |
| Â | All FSHD1 patients | FSHD1 LGE (+) | FSHD1 Fat (+) | |||
|---|---|---|---|---|---|---|
Type of Arrhythmias | Baseline (n = 52) | Follow-up (n = 40) | Baseline (n = 13) | Follow-up (n = 15) | Baseline (n = 7) | Follow-up (n = 12) |
SVT (n) | 1 | 8 | 1 | 3 | – | 5 |
Non-sustained VT n (n) | 1 | 2 | 1 | 2 | 1 | 1 |
Frequent PVC (≥1000/24h) (n) | 2 | 11 | 1 | 8 | 2 | 3 |
AV Block I (n) | 1 | 3 | 1 | 1 | – | 1 |
AV Block II (n) | – | – | – | – | – | – |
LBBB | – | – | – | – | – | – |
RBBB | – | – | – | – | – | – |
LAH | – | – | – | – | – | – |
LGE location and global volume | Â | Â | 13 | 15 | 2 | 3 |
Inferolateral basal (n)) | 7 | 7 | 7 | 7 | – | – |
Anterolateral basal (n) | 2 | 1 | 2 | 1 | – | – |
Septal (n) | 3 | 3 | 3 | 3 | – | – |
Inferior (n) | 1 | 3 | 1 | 3 | – | – |
LGE area - mean (%) | Â | Â | 18.6 | 28.9 | Â | Â |
Fat apical | Â | Â | Â | Â | 7 | 12 |
Medical therapy | Â | Â | Â | Â | Â | Â |
Beta blockers (n) | 1 | 4 | Â | 1 | 1 | 3 |
ACE-I, ARBs (n) | 2 | 7 | 1 | 3 | 1 | 2 |